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yl)ethyl)piperazine derivatives is achieved by a four component cyclo condensation of diacetyl,
aromatic aldehyde, 2-(piperazin-1-yl)ethanamine and ammonium acetate using SO4
2/Y2O3 as a
catalyst in ethanol. The synthesized compounds were characterized by IR, 1H and 13C NMR and
mass spectral studies. All the synthesized compounds were screened for their in vitro antimicrobial
studies. Among the newly synthesized compounds 5d, 5e, 5h and 5m showed excellent antibacterial
and antifungal activities when compared to the standard drugs.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Open access under CC BY-NC-ND license.1. Introduction
Imidazole ring system exhibited a variety of pharmaceutical
activities [1–3] and plays a vital role in biochemical processes.
The core structure of imidazole plays an important role in bio-
logically potent molecules like histidine, histamine and biotin
as well as several drug moieties [4] such as Trifenagrel, Epro-
sartan and Losartan (Fig. 1). It is known that clinically useful
drugs such as miconazole, econazole and oxiconazole (Fig. 2)
containing imidazole moiety exhibit strong antifungal activity.Imidazole derivatives have novel therapeutic activities [5], her-
bicides [6], plant-growth regulators [7], and inhibitors of p38
MAP kinase [5]. Furthermore, recent reports indicate that imi-
dazoles are cytotoxic [8], anticonvulsant [9], anti-inﬂammatory
[10], analgesic [11] and potent inhibitors of protein–protein
interactions [12]. Numerous methods have been reported for
the synthesis of 1,2,4,5-tetrasubstituted imidazoles. The syn-
thesis of 1,2,4,5-tetrasubstituted imidazoles has been carried
out by a four-component condensation of 1,2-diketone with
aldehyde, primary amine and ammonium acetate using micro-
waves [13], heteropolyacid [14], BF3ÆSiO2 [15], silica gel/
NaHSO4 [16] or HClO4–SiO2 [17], ionic liquids [18], L-proline
[19], ZrCl4 [20], InCl3Æ3H2O [21], K5CoW12O40Æ3H2O [22],
molecular iodine [23], silica sulphuric acid [24], NiCl2Æ6H2O/
Al2O3 [25] and CAN [26]. However, the above methods suffer
from one or more disadvantages such as the use of hazardous
organic solvents, tedious work-up conditions, longer reaction
times and large volumes of catalyst loading. Nowadays
sulphated metal and mixed metal oxides gained much more
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736 R. Rajkumar et al.recognition for their signiﬁcant catalytic activity than metal
and mixed metal oxides due to their higher number of acid
sites and larger surface area, which resulted in enhanced cata-
lytic activity [27]. Herein we report a simple one-pot process
for the synthesis of 1,2,4,5-tetrasubstituted imidazoles 5a–m
through a four-component condensation reaction of diacetyl
(1), substituted aldehyde (2), 2-(piperazin-1-yl)ethanamine (3)
and ammonium acetate (4) in the presence of sulphated yttria
(SO4
2/Y2O3), as the best catalyst in ethanol.
2. Experimental
2.1. General methods
The 1H and 13C NMR spectra of the synthesized compounds
in CDCl3 were recorded on a Bruker Avance 400 or
500 MHz NMR spectrometer. The 1H NMR and 13C NMR
were referred, respectively, to TMS as an internal standard
and the central line of CDCl3. IR spectra were recorded by
using a JASCO FT/IR-5300 spectrometer. All reactions were
carried out with freshly distilled solvents. Column chromatog-
raphy was performed on silica gel (100–200 mesh) from Merck
chemical company using methanol and ethyl acetate mixture as
eluent. Solvents were removed under reduced pressure on a
rotary evaporator. Organic layer was dried over anhydrous
Na2SO4. Thin Layer Chromatography was performed on com-
mercial aluminium plates coated with silica gel. The visualiza-
tion of TLC plates was effected by UV and Seebach stain
solution upon heating.
2.2. Preparation of the catalyst
The catalyst with 5 wt.% of SO4
2 loaded with yttrium oxide
(Y2O3) was prepared by the sol–gel method, from 2.7 g of
Y2O3 dispersed in 100 mL ethanol and 3.2 mL of 1 M H2SO4
was added dropwise with vigorous stirring for 4 h. The gel
obtained was ﬁltered, washed and dried in an air oven at
100 C for 12 h. The addition of BaCl2 to the ﬁltrate gave no
precipitate which indicates that all the sulphate ions werecompletely loaded on the gel. This catalyst contained 5 wt.%
of SO4
2/Y2O3.
2.3. General procedure for the preparation of the title compounds
5a–m
In a 50 mL round bottomed ﬂask, diacetyl (1 mmol), aromatic
aldehyde (1 mmol), 2-(piperazin-1-yl)ethanamine (1 mmol)
and ammonium acetate (2 mmol) were introduced in the pres-
ence of SO4
2/Y2O3 (50 mg) in ethanol (20 mL). Then the reac-
tion mixture was stirred at 80 C for 10 h. The progress of the
reaction was monitored by TLC. After completion of the reac-
tion, the volume of the reaction mixture was reduced, diluted
with cold water and extracted with ethyl acetate. The organic
layer was dried over anhydrous Na2SO4 and then the solvent
was removed under reduced pressure. The crude products, thus
obtained were subjected to puriﬁcation by column chromatog-
raphy with silica gel (100–200 mesh size) using 25% methanol
in ethyl acetate as eluent to yield 1,2,4,5-tetrasustituted
imidazoles.
2.3.1. 1-(2-(4,5-Dimethyl-2-phenyl-1H-imidazol-
1-yl)ethyl)piperazine (5a)
Yield 93%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.15 (s, 6H), 2.31 (s,
4H), 2.44 (t, J= 6.8 Hz, 2H), 2.77 (s, 4H), 3.94 (t,
J= 6.8 Hz, 2H), 7.26–7.50 (m, 5H); 13C NMR (CDCl3,
100 MHz) d 9.22, 12.55, 41.91, 44.26, 52.51, 58.36, 123.23,
128.48, 128.84, 131.42, 133.29, 146.00, 177.72. LCMS: calcd:
284, found: 285.
2.3.2. 1-(2-(4,5-Dimethyl-2-(p-tolyl)-1H-imidazol-
1-yl)ethyl)piperazine (5b)
Yield 92%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.11 (s, 6H), 2.32 (d,
J= 10.0 Hz, 7H), 2.41 (t, J= 6.8 Hz, 2H), 2.78 (s, 4H), 2.78
(s, 4H), 3.89 (t, J= 6.8 Hz, 2H), 7.14 (d, J= 7.6 Hz, 2H),
7.33 (d, J= 8.0 Hz, 2H); 13C NMR (CDCl3, 100 MHz) d
9.16, 12.40, 21.25, 23.75, 41.88, 43.72, 51.66, 58.07, 123.05,
128.27, 128.68, 129.20, 132.79, 132.92, 138.47, 146.03, 177.79.
LCMS: calcd: 298, found: 299.
2.3.3. 4-(4,5-Dimethyl-1-(2-(piperazin-1-yl)ethyl)-
1H-imidazol-2-yl)-N,N-dimethylaniline (5c)
Yield 92%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.12 (t, J= 1.6 Hz,
6H), 2.38 (s, 4H), 2.47 (t, J= 7.2 Hz, 2H), 2.83 (s, 4H), 2.94
(s. 6H), 3.93 (t, J= 6.4 Hz, 2H), 6.6 (d, J= 8.4 Hz, 2H),
7.32–7.35 (m, 2H); 13C NMR (CDCl3, 125 MHz) d 9.19,
12.27, 23.56, 29.65, 40.28, 41.93, 44.09, 51.20, 52.13, 53.38,
58.19, 11.90, 118.30, 122.57, 129.72, 132.10, 132.20, 146.58,
150.49, 177.34. LCMS: calcd: 327, found: 328.2.3.4. 1-(2-(2-(4-Fluorophenyl)-4,5-dimethyl-1H-imidazol-1-yl)
ethyl)piperazine (5d)
Yield 91%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.17 (s, 6H), 2.38 (s,
4H), 2.47 (d, J= 5.6 Hz, 2H), 2.84 (s, 4H), 3.94 (d,
J= 5.6 Hz, 2H), 7.09 (t, J= 2.4 Hz, 2H), 7.51 (d,
J= 3.2 Hz, 2H); 13C NMR (CDCl3, 100 MHz) d 9.22, 12.49,
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127.57, 130.70, 130.79, 133.35, 144.99, 161,54, 164.02, 177.55.
LCMS: calcd: 302, found: 303.
2.3.5. 1-(2-(2-(4-Chlorophenyl)-4,5-dimethyl-1H-imidazol-1-
yl)ethyl)piperazine (5e)
Yield 89%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.10 (s, 6H), 2.29 (s,
4H), 2.40 (d, J= 5.2 Hz, 2H), 2.74 (s, 4H), 3.88 (d,
J= 5.2 Hz, 2H), 7.29 (s, 2H), 7.43 (s, 2H); 13C NMR (CDCl3,
100 MHz) d 9.18, 12.49, 42.09, 44.46, 52.86, 58.31, 123.71,
128.67, 129.87, 130.02, 133.54, 134.33, 144.68, 177.98. LCMS:
calcd: 318, found: 319.
2.3.6. 1-(2-(2-(2,4-Dichlorophenyl)-4,5-dimethyl-1H-imidazol-
1-yl)ethyl)piperazine (5f)
Yield 87%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 500 MHz) d 2.14 (d, J= 3.5 Hz,
6H), 2.35 (s, 6H), 2.86 (s, 4H), 3.74 (s, 2H), 7.28–7.44 (m,
3H); 13C NMR (CDCl3, 100 MHz) d 9.09, 12.49, 41.88,
43.28, 51.02, 57.94, 123.09, 127.31, 129.37, 129.57, 133.30,
133.57, 135.13, 136.0, 141.57, 177.34. LCMS: calcd: 352,
found: 353.
2.3.7. 1-(2-(4,5-Dimethyl-2-(4-nitrophenyl)-1H-imidazol-1-
yl)ethyl)piperazine (5g)
Yield 88%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 500 MHz) d 2.14 (s, 3H), 2.17 (s,
3H), 2.46 (s, 4H), 2.53 (s, 2H), 2.89 (s, 4H), 4.02 (s, 2H),
7.75 (d, J= 8.0 Hz, 2H), 8.21 (d, J= 5.5 Hz, 2H); 13C
NMR (CDCl3, 100 MHz) d 9.25, 12.42, 42.57, 43.08, 50.63,
57.71, 123.89, 125.39, 129.10, 134.91, 137.32, 143.47, 147.17,
177.21. LCMS: calcd: 329, found: 330.2.3.8. 1-(2-(2-(3-Bromo-4-ﬂuorophenyl)-4,5-dimethyl-1H-
imidazol-1-yl)ethyl)piperazine (5h)
Yield 91%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.15 (d, J= 6.4 Hz,
6H), 2.45 (s, 4H), 2.52 (d, J= 4.0 Hz, 2H), 2.91 (s, 4H), 3.94
(s, 2H), 7.14 (d, J= 3.6 Hz, 1H), 7.47 (s, 1H), 7.81 (s, 1H);
13C NMR (CDCl3, 100 MHz) d 9.20, 12.41, 42.35, 43.44,
51.20, 57.90, 109.02, 109.23, 116.54, 116.76, 123.84, 128.85,
128.89, 129.51, 129.58, 133.80, 143.50, 177.58. LCMS: calcd:
380, found: 381.
2.3.9. Bromo-4-(4,5-dimethyl-1-(2-(piperazin-1-yl)ethyl)-1H-
imidazol-2-yl)phenol (5i)
Yield 86%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.15 (t, J= 8.0 Hz,
6H), 2.31 (s, 4H), 2.46 (s, 2H), 2.79 (s, 4H), 3.90 (s, 2H),
6.74 (d, J= 8.0 Hz, 1H), 7.11 (d, J= 7.2 Hz, 1H), 7.57 (s,
1H); 13C NMR (CDCl3, 100 MHz) d 9.13, 12.09, 41.86,
44.60, 52.83, 58.23, 111.64, 117.50, 120.80, 122.98, 129.31,
132.06, 133.22, 145.23, 178.67. LCMS: calcd: 378, found: 379.
2.3.10. 1-(2-(2-(3,4-Dimethoxyphenyl)-4,5-dimethyl-1H-
imidazol-1-yl)ethyl)piperazine (5j)
Yield 88%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.44 (s, 6H), 2.49(t, J= 6.8 Hz, 6H), 2.91 (s, 2H), 3.86 (d, J= 4.4 Hz, 6H),
3.96 (t, J= 6.8 Hz, 2H), 6.86–7.07 (m, 3H), 13C NMR
(CDCl3, 100 MHz) d 9.12, 11.95, 22.81, 42.03, 43.18, 50.74,
55.92, 56,06, 57.80, 110.90, 112.56, 121.10, 122.99, 123.10,
132.39, 145.64, 149.05, 149.64, 176.84. LCMS: calcd: 344,
found: 345.
2.3.11. 1-(2-(4,5-Dimethyl-2-(3,4,5-trimethoxyphenyl)-1H-
imidazol-1-yl)ethyl)piperazine (5k)
Yield 91%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.08–2.11 (m, 6H), 2.35
(s, 4H), 2.44 (s, 2H), 2.80 (d, J= 2.4 Hz, 4H), 3.76–3.78 (m,
9H), 3.93 (s, 2H), 6.65 (t, J= 3.2 Hz, 2H); 13C NMR (CDCl3,
100 MHz) d 9.13, 12.36, 42.17, 43.82, 51.91, 56.24, 58.23,
60.84, 106.28, 123.23, 126.62, 132.99, 138.44, 145.71, 153.14,
177.43. LCMS: calcd: 374, found: 375.
2.3.12. 1-(2-(2-(Benzo[d][1,3]dioxol-5-yl)-4,5-dimethyl-1H-
imidazol-1-yl)ethyl)piperazine (5l)
Yield 88%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.12 (d, J= 6.0 Hz,
6H), 2.36 (s, 4H), 2.44 (t, J= 6.8 Hz, 2H), 2.83 (t,
J= 4.4 Hz, 4H), 3.90 (t, J= 7.2 Hz, 2H), 5.93 (s, 2H), 6.77–
7.26 (m, 3H); 13C NMR (CDCl3, 100 MHz) d 9.20, 12.43,
29.62, 41.95, 44.17, 52.38, 58.25, 101.30, 108.32, 109.45,
122.79, 123.03, 125.05, 132.94, 145.60, 147.68, 147.87, 177.80.
LCMS: calcd: 328, found: 329.2.3.13. 1-(2-(4,5-Dimethyl-2-(thiophen-2-yl)-1H-imidazol-1-
yl)ethyl)piperazine (5m)
Yield 87%. Yellow gummy solid (after column chromatogra-
phy). 1H NMR (CDCl3, 400 MHz) d 2.16 (t, J= 6.0 Hz,
6H), 2.50 (t, J= 4.4 Hz, 4H), 2.59 (t, J= 7.2 Hz, 2H), 2.91
(t, J= 4.8 Hz, 4H), 4.08 (t, J= 7.2 Hz, 2H), 7.04–7.32 (m,
3H); 13C NMR (CDCl3, 100 MHz) d 9.17, 12.59, 42.35,
44.29, 52.59, 58.14, 123.98, 125.63, 126.11, 127.37, 133.09,
133.87, 139.69, 177.70. LCMS: calcd: 290, found: 291.2.4. Biological screening
The antimicrobial studies were carried out by following the lit-
erature procedure [28,29] given for the disc diffusion method.
The test organisms were subcultured using a nutrient agar
medium. The tubes containing sterilized medium were inocu-
lated with the respective bacterial strain. After incubation at
37 ± 1 C for 18 h, they were stored in a refrigerator. The
nutrient agar medium was sterilized by autoclaving at 121 C
for 15 min. The petriplates, tubes and ﬂasks plugged with cot-
ton were sterilized in hot-air oven at 160 C for an hour. Into
each sterilized petriplate (20 cm diameter), was poured about
125 ml of molten nutrient agar medium which was already
inoculated with the respective strain of bacterium/fungus
(5 ml of inoculum to 250 ml of nutrient agar medium) asepti-
cally. The plates were left at room temperature aseptically to
allow solidiﬁcation. After solidiﬁcation, the paper discs con-
taining the derivatives were placed at different areas on the
surface of each plate and labelled accordingly.
Each test compound (5 mg) was dissolved in dimethyl
sulphoxide (5 ml Analar grade) to give a concentration of
1000 lg/ml. Ciproﬂoxacin solution was also prepared to give
H3C
O
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NHN
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Scheme 1 Synthesis of 1,2,4,5-tetrasubstituted imidazole
derivatives.
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pH of all the test solutions and control was maintained in
between 2 and 3 using conc. HCl. All the compounds were
tested at dose levels of 1000 lg and DMSO was used as a con-
trol. The solutions of each test compound, control and refer-
ence standard were added separately into the cups and the
plates were kept undisturbed for at least 2 h in a refrigerator
to allow diffusion of the solution properly into nutrient agar
medium. Petri dishes were subsequently incubated at
37 ± 1 C for 24 h. After incubation, the diameter of zone of
inhibition surrounding each of the cups was measured with
the help of an antibiotic zone reader. The results are presented
in Table 3.
3. Results and discussion
3.1. Chemistry
One-pot process for the synthesis of the title compounds (5a–
m) is sketched in Scheme 1. The derivatives of 1-(2-(4,5-
dimethyl-2-phenyl-1H-imidazol-1-yl)ethyl)piperazine (Table 2)
were prepared using one pot multicomponent reaction by con-
densing diacetyl, various aromatic aldehydes, 2-(piperazin-1-
yl)ethanamine and ammonium acetate in 1:1:1:2 ratio in the
presence of sulphated yttria. All the newly synthesized com-
pounds were fully characterized on the basis of spectroscopic
techniques (IR, LC–MS, 1H and 13C NMR spectra).
Initially we started the investigation of the reaction with
diacetyl (1 mmol), 2-(piperazin-1-yl)ethanamine (1 mmol),
benzaldehyde (1 mmol) and ammonium acetate (2 mmol) inTable 1 Optimization of the reaction conditions for compound 5a.
Entry Catalyst Catalyst loading (mol%)
1 No catalyst 
2 Acidic Al2O3 5
3 Acidic Al2O3 10
4 AcOH 5
5 AcOH 10
6 CAN 5
7 CAN 10
8 ZnCl2 5
9 ZnCl2 10
10 I2 5
11 I2 10
12 SO4
2/Y2O3 (5 wt.%) 
a Reaction scale: 1 (1 mmol), 2 (1 mmol), 3 (1 mmol), 4 (2 mmol).ethanol at 80 C in the absence of a catalyst and no product
was observed (Table 1, Entry 1). Then it was worthwhile to
carry out the reaction in the presence of catalysts like acidic
Al2O3, acetic acid (AcOH), Ceric Ammonium Nitrate
(CAN), zinc chloride (ZnCl2), iodine (I2) and sulphated yttria
(SO4
2/Y2O3) and the observed results were summarized below.
The same condensation reaction was carried out at 80 C
using 5 mol% and 10 mol% of acidic Al2O3. We obtained only
14% and 10% yields respectively in 10 h (Table 1, Entry 2 and
3). Further investigation was carried out using 5 mol% and
10 mol% of AcOH as a catalyst for the same condensation
reaction for 10 h yielded only 37% and 33% of the product
respectively in each case (Table 1, Entry 4 and 5).
A similar condensation reaction was carried out at 80 C
for 10 h using 5 and 10 mol% of CAN, yielding 47% and
42% of the corresponding substituted imidazoles (Table 1,
Entry 6 and 7). Then the reaction was attempted with 5 and
10 mol% of ZnCl2 as a catalyst for 10 h and yields were
56% and 53% respectively (Table 1, Entry 8 and 9). Further
investigation was carried out with 5 mol% and 10 mol% of
molecular iodine (I2) as a catalyst for 10 h and yields were
71% and 78%, respectively (Table 1, Entry 10 and 11). How-
ever when sulphated yttria (5 wt.%) was used as a catalyst for
the same condensation reaction for 10 h the yield was signiﬁ-
cantly increased to 93% (Table 1, Entry 12). From the above
observed results, we concluded that the sulphated yttria is
the best catalyst for this condensation reaction.4. Analytical results
The synthesized compounds were characterized by FT-IR, 1H
and 13C NMR and mass spectra. IR spectral data of com-
pounds 5a–m showed characteristic absorption bands at
1700–1665 cm1, which were assigned to C‚N of the imidaz-
ole ring. The numbering followed for explaining NMR spectra
of compound 5a is shown in Fig 3. In 1H NMR spectrum of
representative compound 5a (Fig. 4), the aromatic proton sig-
nal appeared in the region 7.33–7.50 ppm with ﬁve protons
integral value. In the higher frequency region, one triplet
appeared at 3.94 ppm is assigned to methylene protons of C6
carbon. Further the methylene protons of C7 carbon appeared
at 2.44 ppm as a triplet. There are two signals at 2.76 and
2.31 ppm, respectively with eight protons integral in total. Ofa
Temperature (˚C) Time (h) Yield (%)
80 10 
80 10 14
80 10 10
80 10 37
80 10 33
80 10 47
80 10 42
80 10 56
80 10 53
80 10 71
80 10 78
80 10 93
Table 2 Synthesis of 1-(2-(4,5-dimethyl-2-phenyl-1H-imidazol-1-yl)ethyl)piperazine derivatives.a
Entry 1,2-Diketone R-CHO Amine source Products Time (h) Yieldb
a CH3H3C
O O
CHO
NH4OAc
N N
CH3H3C
NHN
10 93
b CH3H3C
O O
CHOH3C
NH4OAc
N N
CH3H3C
NHN
H3C
10 92
c CH3H3C
O O
CHON
H3C
H3C
NH4OAc
N N
CH3H3C
N
HN
NH3C CH3
10 92
d CH3H3C
O O
CHOF
NH4OAc
N N
CH3H3C
N
HN
F
10 91
e CH3H3C
O O
CHOCl
NH4OAc
N N
CH3H3C
N
HN
Cl
10 89
f CH3H3C
O O
CHOCl
Cl
NH4OAc
N N
CH3H3C
NHN
Cl
Cl
10 87
g CH3H3C
O O
CHOO2N
NH4OAc
N N
CH3H3C
N
HN
O2N
10 88
h CH3H3C
O O
CHO
Br
F
NH4OAc
N N
CH3H3C
NHN
F
Br
10 91
(continued on next page)
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Table 2 (continued)
I CH3H3C
O O
CHO
Br
HO
NH4OAc
N N
CH3H3C
N
HN
HO
Br
10 86
j CH3H3C
O O
CHOH3CO
H3CO
NH4OAc
N N
CH3H3C
N
HN
OCH3
H3CO
10 88
k CH3H3C
O O CHO
H3CO
H3CO
H3CO
NH4OAc
N N
CH3H3C
N
HN
OCH3
H3CO
H3CO
10 91
l CH3H3C
O O
CHOO
O
NH4OAc
N N
CH3H3C
NHN
O
O
10 88
m CH3H3C
O O
S CHO
NH4OAc
N N
CH3H3C
NHN
S
10 87
a Diacetyl: benzaldehyde: aminoethylpiperazine: NH4OAc (1 mmol: 1 mmol: 1 mmol: 2 mmol).
b Isolated yield.
740 R. Rajkumar et al.these two signals, the deshielded signal appearing as a singlet
at 2.76 ppm is assigned to two sets of methylene protons
attached to N8, whereas the shielded signal appeared as a sin-
glet at 2.31 ppm is assigned to N11 connected methylene pro-
tons. The two methyl protons of the imidazole ring appeared
at 2.15 ppm as a doublet.
In the 13C NMR spectrum of compound 5a (Fig. 5), the
signal appeared at 177.71 ppm is unambiguously assigned to
imino carbon of the imidazole ring. The aromatic carbonN N
CH3H3C
N
HN 1 2
3
45
6
78
9
10
11
12
13
Figure 3 Numbering of compound 5a.signals appeared in the region 145.99–123.22 ppm. The signals
observed, respectively at 41.90 and 58.36 ppm are assigned to
methylene carbons C6 and C7 and the signal observed at
52.50 ppm is assigned to methylene carbons C10 and C12.
The methylene carbons C9 and C13 connected to N8 appeared
at 44.25 ppm. Two methyl carbons of the imidazole ring
appeared respectively at 9.22 and 12.55 ppm. The signal posi-
tion, splitting pattern and chemical shift values of compounds
5b–m are found to be like that of compound 5a, conﬁrmed the
formation of imidazole derivatives.
4.1. Biological activities
The preliminary antimicrobial activity of compounds 5a–m is
examined using the disc diffusion and serial dilution methods.
The bacterial strains viz., Staphylococcus aureus, Esche-
richia coli, Pseudomonas aeruginosa and Salmonella typhi and
fungal strains viz., Aspergillus niger, Aspergillus ﬂavus, Candida
Table 3 In vitro antibacterial and antifungal activities of compounds 5a–m.
Compound Disc Diﬀusion Method
Bacterial strains Fungal strains
E. coli (Z.I) S. aureus (Z.I) P. aeruginosa (Z.I) S. typhi (Z.I) C. albicans (Z.I) Rhizopus. Sp (Z.I) A. niger (Z.I) A. ﬂavus (Z.I)
5a 08 10 06 04 08 04 04 05
5b 10 08 08 05 08 10 08 10
5c 10 12 08 09 04 05 11 07
5d 15 14 16 15 20 17 22 16
5e 15 15 18 16 18 16 20 18
5f 12 10 10 10 05 09 04 05
5g 08 10 06 04 08 04 10 05
5h 16 16 15 18 19 18 21 19
5i 06 14 06 09 04 05 11 08
5j 08 12 10 05 10 10 06 10
5k 10 13 10 02 06 08 05 10
5l 12 10 06 10 05 09 04 05
5m 16 15 17 14 20 17 16 20
Ciproﬂoxacin 12 15 13 11 – – – –
Amphotericin B – – – – 13 11 12 14
Z.I = zone of inhibition in mm.
Figure 4 1H NMR spectrum of compound 5a.
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Figure 5 13C NMR spectrum of compound 5a.
742 R. Rajkumar et al.albicans and Rhizopus sp. are used in this study. DMSO is used
as a control while ciproﬂoxacin and Amphotericin B are used
as standards, respectively, for bacterial and fungal strains.
It is of interest to ﬁnd that the antibacterial activity was
excellent for compound 5m (with thiophene moiety) against
E. coli when compared with standard as well as remaining
compounds. Regarding S. aureus, excellent activity was
observed for compound 5h (with 3-Br and 4-F substituents).
Compound 5e with p-Cl substituent registered an appreciable
activity against P. aeruginosa and S. typhi.
In the case of antifungal evaluation, compound 5d with p-F
substituent exhibited about 1.5 times increased activity against
C. albicans and almost two fold activity againstA. niger. The thi-
ophene containing imidazole (compound 5m) also had equal
activity like that of compound 5d againstC. albicans. Compound
5h having 3-Br and 4-F substituents was proved to be an excellent
inhibitor for the growth of Rhizopus sp. with 1.5 times increased
activity with respect to the standard drug. Thiophene containing
imidazole (compound 5m) was also having the potential to inhibit
the growth of A. ﬂavus by 1.5 times that of the standard.
From the above structure–activity relationship (SAR)
observed, the overall result of the antimicrobial evaluation is
interpreted as follows:
The zone of inhibition (mm) of compounds 5a–m against
the tested bacterial and fungal strains is given in Table 3.
The investigation of antimicrobial activities revealed that,compounds 5d (ﬂuoro substituted), 5e (chloro substituted),
5h (3-bromo-4-ﬂuoro substituted) and 5m (thiophene substi-
tuted) showed excellent antimicrobial activities when com-
pared to the standard drugs.5. Conclusion
In conclusion a novel series of 1-(2-(4,5-dimethyl-2-phenyl-1H-
imidazol-1-yl)ethyl)piperazine (5a–m) was synthesized and
their structures were conﬁrmed by IR, LC–MS, 1H and 13C
NMR spectra. Synthesized compounds were subjected to anti-
microbial studies and the results revealed that the introduction
of thiophene moiety and halo substitution in the imidazole ring
surprisingly enhanced their antibacterial and antifungal
activities.Acknowledgements
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